Drugs / HRS-7450
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06447415 | Aug 2024 → Mar 2025 | ischemic stroke | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06087094 | Oct → Dec 2023 | stroke disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07233070 | Oct 2025 → Oct 2026 expected | ischemic stroke | Fujian Shengdi Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Jiangsu HengRui Medicine Co., Ltd. | Results 2026 ISC 口头报告︱恒瑞创新药HRS-7450用于急性缺血性卒中患者Ib期研究结果公布 hengrui.com ↗
结果显示 [1] ，HRS-7450作为一种新型溶栓药物，对于发病4.5到24小时急性缺血性卒中患者安全性、耐受性良好，颅内出血发生率较相似人群超窗溶栓研究降低，在一定剂量范围内显示有效。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Jiangsu HengRui Medicine Co., Ltd. | 2026 ISC 口头报告︱恒瑞创新药HRS-7450用于急性缺血性卒中患者Ib期研究结果公布 hengrui.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-7450 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07233070 ↗ |